English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Magnolol
Natural API
Magnolol.jpg
Magnolia officinalis.jpg

Magnolol

Magnolol, a biphenyl-type lignan isolated from the bark of Magnolia officinalis (Magnoliaceae), carries the CAS number 528-43-8. As the primary active component of magnolia bark, it exhibits remarkable ​anti-inflammatory, antibacterial, anxiolytic, and neuroprotective​ properties. Listed as a quality control marker in the Chinese Pharmacopoeia (2020 edition), it was approved by the European Medicines Agency (EMA) in 2023 as a traditional herbal medicine for digestive disorders (EMA/HMPC/39435/2023).

Product Name: Magnolol

IUPAC Name: 5,5'-Diallyl-2,2'-dihydroxybiphenyl

CAS No.​: 528-43-8

Molecular Formula: C18H18O2

    Contact us
    product details
    product description

    description1

    description2

    Magnolol

    Basic information

    Product Name: Magnolol

    IUPAC Name: 5,5'-Diallyl-2,2'-dihydroxybiphenyl

    CAS No.​:  528-43-8

    Molecular Formula: C18H18O2

    Physicochemical Properties:

    Parameter

    Value/Description

    ​Appearance​

    White powder

    ​Melting Point​

    102–104°C

    ​Solubility​

    0.1 mg/mL in water; >50 mg/mL in ethanol/acetone

    ​logP​

    4.2 (moderate lipophilicity)

    ​pKa​

    9.8 (phenolic OH)

    ​Stability​

    Light-sensitive; oxidizes under alkaline conditions

    Quality Standard: CP2020,JP,Customer Made

    Specification

    Test Items

    Standard

    Magnolol(CAS: 528-43-8)

    98% by HPLC

    Loss on drying

    ≤1.0%

    Residue on ignition

    ≤1.0%

    Key Features

    index_10-7

    Metabolic Advantage

    80% oral bioavailability (vs. 1% for curcumin).
    index_10-7

    Multi-Target Action

    Simultaneously activates Nrf2 while inhibiting NF-κB and COX-2.
    index_10-7

    High Safety

    NOAEL (No Observed Adverse Effect Level) = 500 mg/kg/day.

    Pharmacological Mechanisms

    1.Molecular Target Network

    Pharmacological Mechanisms3

    2. Pharmacokinetics

    Absorption

    45% oral bioavailability (significant first-pass effect).

    Distribution

    High brain concentration (brain/plasma ratio=3:1).

    Metabolism

    Hepatic CYP3A4-mediated hydroxylation (forms 4'-hydroxymagnolol).

    Excretion

    Primarily biliary (80% clearance in 48h).Primarily biliary (80% clearance in 48h).

    Clinical Applications​

    Indications & Protocols​

    Condition​

    ​Regimen​

    ​Evidence​

    ​Anxiety Disorder​

    50 mg tid ×4 weeks

    ↓40% HAMA score*

    ​Periodontitis​

    0.5% topical gel

    ↓50% gingival index

    ​Type 2 Diabetes​

    100 mg/day (Phase II)

    ↓0.8% HbA1c

    *Randomized double-blind trial (n=200)

    Special Populations​

    Hepatic Impairment: Reduce dose 50% (Child-Pugh B).

    Epilepsy: Use cautiously (GABAergic action may lower seizure threshold).

    Dosage and Administration

    Formulations​

    Tablets: 25 mg/tablet (β-cyclodextrin inclusion complex).

    Gel: 0.5% oral formulation (carbomer base).

    Injection: 10 mg/mL (dilute in 5% glucose).

    Dosing Guidelines

    Use​

    ​Dose​

    ​Duration​

    ​Anxiolytic​

    50–100 mg/day

    4–8 weeks

    ​Topical Anti-Inflammatory​

    Apply bid-qid

    Until symptom relief

    ​Metabolic Improvement​

    100–200 mg/day

    12 weeks

    Safety Evaluation

    Adverse Reactions

    System​

    ​Incidence​

    ​Manifestations​

    ​CNS​

    3%

    Mild drowsiness

    ​Gastrointestinal​

    5%

    Transient nausea

    ​Hypersensitivity​

    0.2%

    Contact dermatitis

    Contraindications & Interactions​

    Absolute CI:
    Hypersensitivity to GABAergics (e.g., benzodiazepines).

    Active acute hepatitis.
    l Cautions:CYP3A4 inhibitors (e.g., ketoconazole): ↑2× plasma concentration.

    Research Progress Green max

    1.Novel Formulations​

    Nanoemulsions: ↑Oral bioavailability to 75%.

    Transdermal Patches: For chronic pain (Patent WO202311688).

    2.New Indications

    Alzheimer’s Disease: Reduces Aβ plaques (↓40% in animal models).

    Non-Alcoholic Fatty Liver: Inhibits hepatic stellate cell activation (↓35% collagen deposition).

    Magnolia officinalis

    Please Send me email and you can get more what you want.

    Such as product of  Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.

    Our experts will solve them in no time.